Skye Bioscience Inc
NASDAQ:SKYE

Watchlist Manager
Skye Bioscience Inc Logo
Skye Bioscience Inc
NASDAQ:SKYE
Watchlist
Price: 5.39 USD -2% Market Closed
Market Cap: 163.5m USD
Have any thoughts about
Skye Bioscience Inc?
Write Note

Intrinsic Value

SKYE's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one SKYE stock under the Base Case scenario is 2.35 USD. Compared to the current market price of 5.39 USD, Skye Bioscience Inc is Overvalued by 56%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SKYE Intrinsic Value
2.35 USD
Overvaluation 56%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Skye Bioscience Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SKYE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SKYE?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Skye Bioscience Inc

Provide an overview of the primary business activities
of Skye Bioscience Inc.

What unique competitive advantages
does Skye Bioscience Inc hold over its rivals?

What risks and challenges
does Skye Bioscience Inc face in the near future?

Has there been any significant insider trading activity
in Skye Bioscience Inc recently?

Summarize the latest earnings call
of Skye Bioscience Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Skye Bioscience Inc.

Provide P/S
for Skye Bioscience Inc.

Provide P/E
for Skye Bioscience Inc.

Provide P/OCF
for Skye Bioscience Inc.

Provide P/FCFE
for Skye Bioscience Inc.

Provide P/B
for Skye Bioscience Inc.

Provide EV/S
for Skye Bioscience Inc.

Provide EV/GP
for Skye Bioscience Inc.

Provide EV/EBITDA
for Skye Bioscience Inc.

Provide EV/EBIT
for Skye Bioscience Inc.

Provide EV/OCF
for Skye Bioscience Inc.

Provide EV/FCFF
for Skye Bioscience Inc.

Provide EV/IC
for Skye Bioscience Inc.

Show me price targets
for Skye Bioscience Inc made by professional analysts.

What are the Revenue projections
for Skye Bioscience Inc?

How accurate were the past Revenue estimates
for Skye Bioscience Inc?

What are the Net Income projections
for Skye Bioscience Inc?

How accurate were the past Net Income estimates
for Skye Bioscience Inc?

What are the EPS projections
for Skye Bioscience Inc?

How accurate were the past EPS estimates
for Skye Bioscience Inc?

What are the EBIT projections
for Skye Bioscience Inc?

How accurate were the past EBIT estimates
for Skye Bioscience Inc?

Compare the revenue forecasts
for Skye Bioscience Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Skye Bioscience Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Skye Bioscience Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Skye Bioscience Inc compared to its peers.

Compare the P/E ratios
of Skye Bioscience Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Skye Bioscience Inc with its peers.

Analyze the financial leverage
of Skye Bioscience Inc compared to its main competitors.

Show all profitability ratios
for Skye Bioscience Inc.

Provide ROE
for Skye Bioscience Inc.

Provide ROA
for Skye Bioscience Inc.

Provide ROIC
for Skye Bioscience Inc.

Provide ROCE
for Skye Bioscience Inc.

Provide Gross Margin
for Skye Bioscience Inc.

Provide Operating Margin
for Skye Bioscience Inc.

Provide Net Margin
for Skye Bioscience Inc.

Provide FCF Margin
for Skye Bioscience Inc.

Show all solvency ratios
for Skye Bioscience Inc.

Provide D/E Ratio
for Skye Bioscience Inc.

Provide D/A Ratio
for Skye Bioscience Inc.

Provide Interest Coverage Ratio
for Skye Bioscience Inc.

Provide Altman Z-Score Ratio
for Skye Bioscience Inc.

Provide Quick Ratio
for Skye Bioscience Inc.

Provide Current Ratio
for Skye Bioscience Inc.

Provide Cash Ratio
for Skye Bioscience Inc.

What is the historical Revenue growth
over the last 5 years for Skye Bioscience Inc?

What is the historical Net Income growth
over the last 5 years for Skye Bioscience Inc?

What is the current Free Cash Flow
of Skye Bioscience Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Skye Bioscience Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Skye Bioscience Inc

Current Assets 87m
Cash & Short-Term Investments 76.3m
Receivables 20
Other Current Assets 10.7m
Non-Current Assets 257.1k
PP&E 248.8k
Other Non-Current Assets 8.3k
Current Liabilities 14.3m
Accounts Payable 1.1m
Accrued Liabilities 2.1m
Short-Term Debt 4.9m
Other Current Liabilities 6.2m
Non-Current Liabilities 129.9k
Other Non-Current Liabilities 129.9k
Efficiency

Earnings Waterfall
Skye Bioscience Inc

Revenue
0 USD
Operating Expenses
-43.3m USD
Operating Income
-43.3m USD
Other Expenses
1.1m USD
Net Income
-42.3m USD

Free Cash Flow Analysis
Skye Bioscience Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SKYE Profitability Score
Profitability Due Diligence

Skye Bioscience Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
ROE is Increasing
Negative Free Cash Flow
Negative Operating Income
41/100
Profitability
Score

Skye Bioscience Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

SKYE Solvency Score
Solvency Due Diligence

Skye Bioscience Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Skye Bioscience Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SKYE Price Targets Summary
Skye Bioscience Inc

Wall Street analysts forecast SKYE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SKYE is 18.36 USD with a low forecast of 14.14 USD and a high forecast of 22.05 USD.

Lowest
Price Target
14.14 USD
162% Upside
Average
Price Target
18.36 USD
241% Upside
Highest
Price Target
22.05 USD
309% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SKYE?

Click here to dive deeper.

Dividends

Skye Bioscience Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SKYE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SKYE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Skye Bioscience Inc Logo
Skye Bioscience Inc

Country

United States of America

Industry

Biotechnology

Market Cap

151.3m USD

Dividend Yield

0%

Description

Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.

Contact

CALIFORNIA
San Diego
11250 El Camino Real, Suite 100
+18584100266.0
skyebioscience.com

IPO

2014-02-24

Employees

9

Officers

Chief Financial Officer
Ms. Kaitlyn Melanie Arsenault CPA
Chief Scientific Officer
Dr. Christopher G. Twitty Ph.D.
Chief Development Officer
Mr. Tu Diep M.Sc.
Chief Medical Officer
Dr. Puneet S. Arora FACE, M.D., M.S.

See Also

Discover More
What is the Intrinsic Value of one SKYE stock?

The intrinsic value of one SKYE stock under the Base Case scenario is 2.35 USD.

Is SKYE stock undervalued or overvalued?

Compared to the current market price of 5.39 USD, Skye Bioscience Inc is Overvalued by 56%.

Back to Top